Improving the treatment of patients with acute coronary syndrome

The aim of the study is to adapt the previously standardized treatment of ACS patients to the individual circumstances of those affected in order to achieve the best possible risk reduction for bleeding and thrombotic complications in equal measure. It is therefore about improved treatment options and individualized therapy with already approved drugs.

Alzheimer-21: Studies on Alzheimer's dementia in people with Down syndrome

People with trisomy 21 face many challenges throughout their lives. Thanks to numerous socio-political and medical advances in recent decades, many people with trisomy 21 are now able to lead independent and self-determined lives. This makes it all the more dramatic that these people are at a high risk of suffering from severe memory disorders in old age. The reason for this lies in a special feature of chromosome 21, which contains a gene that is important in Alzheimer's disease, the amyloid precursor protein (APP) gene. Due to the threefold occurrence of this gene, people with Down syndrome can develop severe memory disorders after the age of 30, which are very similar to Alzheimer's disease. The development of memory disorders in patients with trisomy 21 is often accompanied by behavioral disorders and in many cases destroys years of hard-won autonomy. When this happens, the relatives who have otherwise taken over the care often reach their limits.

However, behavioral abnormalities in people with a trisomy 21 are by no means proof of the development of dementia. Rather, numerous other diseases, some of which are easily treatable, can lead to changes in everyday behavior. For example, in addition to visual and hearing disorders, metabolic disorders such as hypothyroidism or night-time sleep disturbances can also be considered. We offer a wide range of examination methods in our specialist outpatient clinic to ensure the diagnosis of Alzheimer's dementia. Our aim is to identify treatable causes of behavioral abnormalities. In addition, we would like to provide patients and their relatives with advice in the event of Alzheimer's dementia. However, the services offered by our outpatient clinic cannot and should not replace regular care by a general practitioner or specialist.

Biomarker study of familial Alzheimer's dementia (DIAN)

DIAN (Dominantly Inherited Alzheimer Network) stands for the international network for the study of the familial form of Alzheimer's disease. It was founded in the USA to improve research into the genetic forms of Alzheimer's disease and now has sites all over the world. One of the two German study centers (in addition to Tübingen) was established at the German Center for Neurodegenerative Diseases in Munich (DZNE) in close cooperation with the Neurological Clinic of the LMU, Campus Großhadern.

Peaches study

Does childhood obesity begin in the womb? An obesity risk screening for newborns.

http://www.klinikum.uni-muenchen.de/Peaches-Studie/de/index.html

Chart study

Study description: Comparison of 6% hydroxyethyl starch and 5% human albumin for volume replacement therapy in patients undergoing bladder removal (cystectomy).

Study objective: Primary: To compare the effects of human albumin (HA) and hydroxyethyl starch (HES) - used in perioperative volume replacement therapy - on renal function in patients undergoing cystectomy with the aim of demonstrating the superiority of HA over HES
Secondary: To investigate the influence of HA or HES on other laboratory and clinical parameters, hospital and intensive care stay, acute kidney injury and pruritus.

Improving the treatment of patients with acute coronary syndrome

The aim of the study is to adapt the previously standardized treatment of ACS patients to the individual circumstances of those affected in order to achieve the best possible risk reduction for bleeding and thrombotic complications in equal measure. It is therefore about improved treatment options and individualized therapy with already approved drugs.

Study for patients with spinal muscular atrophy (SMA)

Patient survey: Effects of spinal muscular atrophy on the life situation of patients and their environment

To the patient survey

Alzheimer-21: Studies on Alzheimer's dementia in people with Down syndrome

People with trisomy 21 face many challenges throughout their lives. Thanks to numerous socio-political and medical advances in recent decades, many people with trisomy 21 are now able to lead independent and self-determined lives. This makes it all the more dramatic that these people are at a high risk of suffering from severe memory disorders in old age. The reason for this lies in a special feature of chromosome 21, which contains a gene that is important in Alzheimer's disease, the amyloid precursor protein (APP) gene. Due to the threefold occurrence of this gene, people with Down syndrome can develop severe memory disorders after the age of 30, which are very similar to Alzheimer's disease. The development of memory disorders in patients with trisomy 21 is often accompanied by behavioral disorders and in many cases destroys years of hard-won autonomy. When this happens, relatives who have otherwise taken over the care often reach their limits.

However, behavioral abnormalities in people with trisomy 21 are by no means proof of the development of dementia. Rather, numerous other diseases, some of which are easily treatable, can lead to changes in everyday behavior. For example, in addition to visual and hearing disorders, metabolic disorders such as hypothyroidism or night-time sleep disturbances can also be considered. We offer a wide range of examination methods in our specialist outpatient clinic to ensure the diagnosis of Alzheimer's dementia. Our aim is to identify treatable causes of behavioral abnormalities. In addition, we would like to provide patients and their relatives with advice in the event of Alzheimer's dementia. However, the services offered by our outpatient clinic cannot and should not replace regular care by a general practitioner or specialist.

Study to investigate the clinical course of dysferlinopathies

This study is aimed at patients with a genetically confirmed diagnosis of a dysferlinopathy. This includes the most common manifestations such as limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM), but also all other clinical manifestations associated with genetic defects in the "dysferlin" gene.

about the study

Proteus study

What do we want to achieve with this project?

The best nutrition for babies is breast milk. However, breastfeeding is not always possible and infant formula (industrial infant milk) must be used. Commercial infant formula is of good quality. With the Proteus project, we want to try to improve this quality even further. In recent years, it has been shown that the protein composition of infant formula in particular can still be improved. With this study, we are investigating whether infant formula with a lower protein content is better than normal infant formula.

What is being done?

The Proteus study can be started from birth until 45 days after birth and continues until 6 months of age. During this time, you would come to Dr. von Hauner Children's Hospital three times. During these visits, your child's height, weight and body fat percentage will be measured, among other things.

There are three study groups: one of the three groups will be the breastfed comparison group, the other two groups will receive the study milk. The study milk is a normal infant formula or an infant formula with a lower protein content. A random draw is made to determine which of the two study milks your child will receive (randomization). The researchers have no influence on the result of the randomization (double-blind).

Who can take part?

All children up to the age of 45 days who are either fully breastfed or have already been fully weaned can take part. The children should be born between the 37th and 42nd week of pregnancy and not be twins/ multiples.

Would you like more information or would you like to take part in the study? You are welcome to contact us at

E-mail

or call us on 089/4400 -57767 /-57707 /-53486.

The study team can give you more information and answer your questions. You can then decide whether you would like to take part in the study.

Info sheet on the Porteus Study

Biomarker study of familial Alzheimer's dementia (DIAN)

DIAN (Dominantly Inherited Alzheimer Network) stands for the international network for the study of the familial form of Alzheimer's disease. It was founded in the USA to improve research into the genetic forms of Alzheimer's disease and now has sites all over the world. One of the two German study centers (in addition to Tübingen) was established at the German Center for Neurodegenerative Diseases in Munich (DZNE) in close cooperation with the Neurological Clinic of the LMU, Campus Großhadern.

FTLD Consortium & DESCRIBE-FTD

Studies on the spectrum of frontotemporal lobar degeneration

The term frontotemporal lobar degeneration (FTLD) covers a spectrum of neurodegenerative diseases that predominantly affect the frontal and temporal lobes of the brain. Initially, the term Pick's disease was coined for this group of diseases, but the name and classification of frontotemporal lobar degeneration has been repeatedly changed and hotly debated. We currently summarize the following diseases under the FTLD spectrum:

• Frontotemporal dementia (FTD) as a behavioral variant,
• primary non-fluent aphasia (PNFA) and
• semantic dementia (SD) as linguistic variants,
• amyotrophic lateral sclerosis with frontotemporal dementia (ALS+FTD),
• corticobasal syndrome (CBS) and
• progressive supranuclear palsy (PSP).

Frontotemporal dementia (FTD) can lead to changes in language and behavior as well as memory impairment. The aim of the FTLD consortium and the DESCRIBE-FTD study is to describe the course of FTD in its various clinical manifestations in detail, to gain a better understanding of the underlying pathology and to identify parameters that enable diagnosis and prediction of the course of the disease. This should lead to a better understanding of the causes of the disease in the long term and create the conditions for more efficient and earlier therapies.

Further information on the homepage of the DZNE
Further information on the homepage of the Neurological Clinic

GENFI study

The Genetic Frontotemporal dementia Initiative (GENFI) is a collaboration of numerous research centers in Europe and Canada with a common interest in familial frontotemporal dementia (FTD). The coordinator is Dr. Jonathan Rohrer in London. The study aims to gain a better understanding of hereditary FTD, particularly when caused by mutations in the genes for progranulin (GRN), for the tau protein (MAPT) and in c9orf72. There are already promising therapeutic approaches for the treatment of these diseases, but many questions, such as the exact course of the disease and its measurement or the best time to start treatment, still need to be answered.

Further information on the Genetic FTD Initiative
Further information on the homepage of the Neurological Clinic

Study to investigate the clinical course of dysferlinopathies

This study is aimed at patients with a genetically confirmed diagnosis of a dysferlinopathy. This includes the most common manifestations such as limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM), but also all other clinical manifestations associated with genetic defects in the "dysferlin" gene.

about the study

Biomarker study of familial Alzheimer's dementia (DIAN)

DIAN (Dominantly Inherited Alzheimer Network) stands for the international network for the study of the familial form of Alzheimer's disease. It was founded in the USA to improve research into the genetic forms of Alzheimer's disease and now has sites all over the world. One of the two German study centers (in addition to Tübingen) was established at the German Center for Neurodegenerative Diseases in Munich (DZNE) in close cooperation with the Neurological Clinic of the LMU, Campus Großhadern.

Vaccine against rabies

Rabies infection is a viral disease and is usually transmitted through bites, scratches or licking of wounds by rabid mammals (especially dogs, monkeys, bats) in many countries around the world. If the disease breaks out, it is fatal in almost all cases. There is currently no effective treatment.

Travelers can protect themselves with an approved vaccination before starting their journey. Severe allergic reactions caused by the immunoglobulin are possible. The procurement and necessary cold storage of modern rabies vaccines is also a problem in some regions of the world.

The company CureVac GmbH has developed a process that uses a messenger RNA (messenger RNA) to produce protection against the rabies virus. The messenger RNA serves as a blueprint for a vaccine that the body's own cells can produce themselves and thus trigger an immune response. As a vaccination to prevent rabies, this method has been successfully tested for the first time since October 2013 in a phase I safety and efficacy study on 101 test subjects at the Tropical Institute in Munich.

The new vaccine is being tested on healthy adults as part of a clinical trial. Each study participant will receive one or two vaccinations at different doses, depending on the group. The aim of the study is to test the safety, tolerability and effectiveness of the new vaccine.

For further information, please refer to the attached information sheet (PDF):
Information on participation in the rabies vaccination study

ToMI Study

About the ToMI study (Toddler Milk Intervention Trial)

Study to investigate the clinical course of dysferlinopathies

This study is aimed at patients with a genetically confirmed diagnosis of a dysferlinopathy. This includes the most common manifestations such as limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM), but also all other clinical manifestations associated with genetic defects in the "dysferlin" gene.

about the study

Introvision for migraine and headache

IntroMig: randomized waiting list control study with non-drug treatment

A study on the effectiveness of Introvision in patients with migraine is being conducted at the Neurology Clinic of the University of Munich (Großhadern Campus) in collaboration with the University of Hamburg. Introvision according to Prof. Angelika C. Wagner (University of Hamburg) is a method of emotional self-regulation that uses a specially developed perception technique (Konstatierendes Aufmerksames Wahrnehmen: KAW). As migraine patients have impaired stimulus processing (reduced habituation), Introvision could be particularly effective here, and not only due to the lasting reduction in stress.

Migraine sufferers with at least 5 headache days per month up to chronic migraine can participate and are asked to keep a headache calendar for approx. 6 months and not to change their preventive medication and non-drug measures.

Study participants then learn the KAW perception technique and the theoretical background of Introvision in six two-hour courses with video support from Hamburg. This is followed by three individual sessions via video conference. The waiting list group only starts attending the course six weeks later. The primary endpoint is the change in headache days 3 months after Introvision compared to the waiting list group before course participation. Patients are currently being recruited.

Link to the Migraine Study flyer
Please contact Dr. Monika Empl by email

More information:
Introvision for migraine
Neurological Clinic and Polyclinic

OPTIMISTIC: Observational study on myotonic dystrophy type I

European observational study on myotonic dystrophy type I
("Observational Prolonged Trial In Myotonic Dystrophy type I to Improve Stamina,
a Target Identification Collaboration", OPTIMISTIC)

about the study

Vaccine against rabies

Rabies infection is a viral disease and is usually transmitted through bites, scratches or licking of wounds by rabid mammals (especially dogs, monkeys, bats) in many countries around the world. If the disease breaks out, it is fatal in almost all cases. There is currently no effective treatment.

Travelers can protect themselves with an approved vaccination before starting their journey. Severe allergic reactions caused by the immunoglobulin are possible. The procurement and necessary cold storage of modern rabies vaccines is also a problem in some regions of the world.

The company CureVac GmbH has developed a process that uses a messenger RNA (messenger RNA) to produce protection against the rabies virus. The messenger RNA serves as a blueprint for a vaccine that the body's own cells can produce themselves and thus trigger an immune response. As a vaccination to prevent rabies, this method has been successfully tested for the first time since October 2013 in a phase I safety and efficacy study on 101 test subjects at the Tropical Institute in Munich.

The new vaccine is being tested on healthy adults as part of a clinical trial. Each study participant will receive one or two vaccinations at different doses, depending on the group. The aim of the study is to test the safety, tolerability and effectiveness of the new vaccine.

For further information, please refer to the attached information sheet (PDF):
Information on participation in the rabies vaccination study

OPTIMISTIC: Observational study on myotonic dystrophy type I

European observational study on myotonic dystrophy type I
("Observational Prolonged Trial In Myotonic Dystrophy type I to Improve Stamina,
a Target Identification Collaboration", OPTIMISTIC)

about the study

Peaches study

Does childhood obesity begin in the womb? An obesity risk screening for newborns.

http://www.klinikum.uni-muenchen.de/Peaches-Studie/de/index.html

Proteus study

What do we want to achieve with this project?

The best nutrition for babies is breast milk. However, breastfeeding is not always possible and infant formula (industrial infant milk) must be used. Commercial infant formula is of good quality. With the Proteus project, we want to try to improve this quality even further. In recent years, it has been shown that the protein composition of infant formula in particular can still be improved. With this study, we are investigating whether infant formula with a lower protein content is better than normal infant formula.

What is being done?

The Proteus study can be started from birth until 45 days after birth and continues until 6 months of age. During this time, you would visit us three times at Dr. von Hauner's Children's Hospital. During these visits, your child's height, weight and body fat percentage will be measured, among other things.

There are three study groups: one of the three groups will be the breastfed comparison group, the other two groups will receive the study milk. The study milk is a normal infant formula or an infant formula with a lower protein content. A random draw is made to determine which of the two study milks your child will receive (randomization). The researchers have no influence on the result of the randomization (double-blind).

Who can take part?

All children up to the age of 45 days who are either fully breastfed or have already been fully weaned can take part. The children should be born between the 37th and 42nd week of pregnancy and not be twins/ multiples.

Would you like more information or would you like to take part in the study? You are welcome to contact us at

E-mail

or call us on 089/4400 -57767 /-57707 /-53486.

The study team can give you more information and answer your questions. You can then decide whether you would like to take part in the study.

Info sheet on the Porteus Study

Study for patients with spinal muscular atrophy (SMA)

Patient survey: Effects of spinal muscular atrophy on the life situation of patients and their environment

patient survey

FTLD Consortium & DESCRIBE-FTD

Studies on the spectrum of frontotemporal lobar degeneration

The term frontotemporal lobar degeneration (FTLD) covers a spectrum of neurodegenerative diseases that predominantly affect the frontal and temporal lobes of the brain. Initially, the term Pick's disease was coined for this group of diseases, but the name and classification of frontotemporal lobar degeneration has been repeatedly changed and hotly debated. We currently summarize the following diseases under the FTLD spectrum:

• Frontotemporal dementia (FTD) as a behavioral variant,
• primary non-fluent aphasia (PNFA) and
• semantic dementia (SD) as linguistic variants,
• amyotrophic lateral sclerosis with frontotemporal dementia (ALS+FTD),
• corticobasal syndrome (CBS) and
• progressive supranuclear palsy (PSP).

Frontotemporal dementia (FTD) can lead to changes in language and behavior as well as memory impairment. The aim of the FTLD consortium and the DESCRIBE-FTD study is to describe the course of FTD in its various clinical manifestations in detail, to gain a better understanding of the underlying pathology and to identify parameters that enable diagnosis and prediction of the course of the disease. This should lead to a better understanding of the causes of the disease in the long term and create the conditions for more efficient and earlier therapies.

GENFI study

The Genetic Frontotemporal dementia Initiative (GENFI) is a collaboration of numerous research centers in Europe and Canada with a common interest in familial frontotemporal dementia (FTD). The coordinator is Dr. Jonathan Rohrer in London. The study aims to gain a better understanding of hereditary FTD, particularly when caused by mutations in the genes for progranulin (GRN), for the tau protein (MAPT) and in c9orf72. There are already promising therapeutic approaches for the treatment of these diseases, but many questions, such as the exact course of the disease and its measurement or the best time to start treatment, still need to be answered.

Proteus study

What do we want to achieve with this project?

The best nutrition for babies is breast milk. However, breastfeeding is not always possible and infant formula (industrial infant milk) must be used. Commercial infant formula is of good quality. With the Proteus project, we want to try to improve this quality even further. In recent years, it has been shown that the protein composition of infant formula in particular can still be improved. With this study, we are investigating whether infant formula with a lower protein content is better than normal infant formula.

What is being done?

The Proteus study can be started from birth until 45 days after birth and continues until 6 months of age. During this time, you would visit us three times at Dr. von Hauner's Children's Hospital. During these visits, your child's height, weight and body fat percentage will be measured, among other things.

There are three study groups: one of the three groups will be the breastfed comparison group, the other two groups will receive the study milk. The study milk is a normal infant formula or an infant formula with a lower protein content. A random draw is made to determine which of the two study milks your child will receive (randomization). The researchers have no influence on the result of the randomization (double-blind).

Who can take part?

All children up to the age of 45 days who are either fully breastfed or have already been fully weaned can take part. The children should be born between the 37th and 42nd week of pregnancy and not be twins/ multiples.

Would you like more information or would you like to take part in the study? You are welcome to contact us at

E-mail

or call us on 089/4400 -57767 /-57707 /-53486.

The study team can give you more information and answer your questions. You can then decide whether you would like to take part in the study.

Info sheet on the Porteus Study

Study Center

The DSGZ study center supports scientists in clinical research including design, biometrics (in close cooperation with the IBE), data management, regulatory compliance (in cooperation with the CSCLMU), insurance, training, funding. It offers infrastructure such as study assistance, quality management, electronic data capture (via eCRF), trial management system (TrackDB), contact to trial sites with experience in clinical vestibular research.

The DSGZ study center is also open to cooperation with institutions outside the DSGZ, for which, however, the CSCLMU should be the first point of contact within the KUM (Klinikum der Universität München).

Study for patients with spinal muscular atrophy (SMA)

Patient survey: Effects of spinal muscular atrophy on the life situation of patients and their environment

patient survey

ToMI Study

About the ToMI study (Toddler Milk Intervention Trial)

Improving the treatment of patients with acute coronary syndrome

The aim of the study is to adapt the previously standardized treatment of ACS patients to the individual circumstances of those affected in order to achieve the best possible risk reduction for bleeding and thrombotic complications in equal measure. It is therefore about improved treatment options and individualized therapy with already approved drugs.

Alzheimer-21: Studies on Alzheimer's dementia in people with Down syndrome

People with trisomy 21 face many challenges throughout their lives. Thanks to numerous socio-political and medical advances in recent decades, many people with trisomy 21 are now able to lead independent and self-determined lives. This makes it all the more dramatic that these people are at a high risk of suffering from severe memory disorders in old age. The reason for this lies in a special feature of chromosome 21, which contains a gene that is important in Alzheimer's disease, the amyloid precursor protein (APP) gene. Due to the threefold occurrence of this gene, people with Down syndrome can develop severe memory disorders after the age of 30, which are very similar to Alzheimer's disease. The development of memory disorders in patients with trisomy 21 is often accompanied by behavioral disorders and in many cases destroys years of hard-won autonomy. When this happens, relatives who have otherwise taken over the care often reach their limits.

However, behavioral abnormalities in people with trisomy 21 are by no means proof of the development of dementia. Rather, numerous other diseases, some of which are easily treatable, can lead to changes in everyday behavior. For example, in addition to visual and hearing disorders, metabolic disorders such as hypothyroidism or night-time sleep disturbances can also be considered. We offer a wide range of examination methods in our specialist outpatient clinic to ensure the diagnosis of Alzheimer's dementia. Our aim is to identify treatable causes of behavioral abnormalities. In addition, we would like to provide patients and their relatives with advice in the event of Alzheimer's dementia. However, the services offered by our outpatient clinic cannot and should not replace regular care by a general practitioner or specialist.

OPTIMISTIC: Observational study on myotonic dystrophy type I

European observational study on myotonic dystrophy type I
("Observational Prolonged Trial In Myotonic Dystrophy type I to Improve Stamina,
a Target Identification Collaboration", OPTIMISTIC)

about the study

Vaccine against rabies

Rabies infection is a viral disease and is usually transmitted through bites, scratches or licking of wounds by rabid mammals (especially dogs, monkeys, bats) in many countries around the world. If the disease breaks out, it is fatal in almost all cases. There is currently no effective treatment.

Travelers can protect themselves with an approved vaccination before starting their journey. Severe allergic reactions caused by the immunoglobulin are possible. The procurement and necessary cold storage of modern rabies vaccines is also a problem in some regions of the world.

The company CureVac GmbH has developed a process that uses a messenger RNA (messenger RNA) to produce protection against the rabies virus. The messenger RNA serves as a blueprint for a vaccine that the body's own cells can produce themselves and thus trigger an immune response. As a vaccination to prevent rabies, this method has been successfully tested for the first time since October 2013 in a phase I safety and efficacy study on 101 test subjects at the Tropical Institute in Munich.

The new vaccine is being tested on healthy adults as part of a clinical trial. Each study participant will receive one or two vaccinations at different doses, depending on the group. The aim of the study is to test the safety, tolerability and effectiveness of the new vaccine.

For further information, please refer to the attached information sheet (PDF):
Information on participation in the rabies vaccination study

ToMI Study

About the ToMI study (Toddler Milk Intervention Trial)

Typia study

We are looking for healthy control subjects to complete our short online personality questionnaire. We are a group of employees at the Clinic for Psychiatry and Psychotherapy at the LMU in Munich and at the University of Bonn who are looking for people interested in a study called "TYPIA". The study investigates the cognitive and psychological basis of schizophrenia.

For this we also need healthy control subjects, for which you might be suitable. The results of the study should help us to gain a better understanding of the development of schizophrenia in order to possibly develop more effective treatment options. We would therefore be very grateful if you could take some time (approx. 3 to 5 minutes) to complete the questionnaire.

Go to our homepage http://www.typia.de to get started!

We will be giving away 20 cash prizes worth €10 among all participants.

You also have the chance to take part in a further study in which you will receive an expense allowance of €80 + travel costs and - if you are interested - pictures of your brain.

Postcards Typia Study

Chart study

• Study description: Comparison of 6% hydroxyethyl starch and 5% human albumin for volume replacement therapy in patients undergoing bladder removal (cystectomy).
• Study objective: Primary: To compare the effects of human albumin (HA) and hydroxyethyl starch (HES) - used in perioperative volume replacement therapy - on renal function in patients undergoing cystectomy with the aim of demonstrating the superiority of HA over HES
• Secondary: Investigation of the influence of HA or HES on other laboratory and clinical parameters, hospital and intensive care stay, acute kidney injury and pruritus
• Contact: Department of Anaesthesiology Prof. Dr. Markus REHM E-mail: Markus.Rehm@med.uni-muenchen.de

FTLD Consortium & DESCRIBE-FTD

Studies on the spectrum of frontotemporal lobar degeneration

The term frontotemporal lobar degeneration (FTLD) covers a spectrum of neurodegenerative diseases that predominantly affect the frontal and temporal lobes of the brain. Initially, the term Pick's disease was coined for this group of diseases, but the name and classification of frontotemporal lobar degeneration has been repeatedly changed and hotly debated. We currently summarize the following diseases under the FTLD spectrum:

• Frontotemporal dementia (FTD) as a behavioral variant,
• primary non-fluent aphasia (PNFA) and
• semantic dementia (SD) as linguistic variants,
• amyotrophic lateral sclerosis with frontotemporal dementia (ALS+FTD),
• corticobasal syndrome (CBS) and
• progressive supranuclear palsy (PSP).

Frontotemporal dementia (FTD) can lead to changes in language and behavior as well as memory impairment. The aim of the FTLD consortium and the DESCRIBE-FTD study is to describe the course of FTD in its various clinical manifestations in detail, to gain a better understanding of the underlying pathology and to identify parameters that enable diagnosis and prediction of the course of the disease. This should lead to a better understanding of the causes of the disease in the long term and create the conditions for more efficient and earlier therapies.

GENFI study

The Genetic Frontotemporal dementia Initiative (GENFI) is a collaboration of numerous research centers in Europe and Canada with a common interest in familial frontotemporal dementia (FTD). The coordinator is Dr. Jonathan Rohrer in London. The study aims to gain a better understanding of hereditary FTD, particularly when caused by mutations in the genes for progranulin (GRN), for the tau protein (MAPT) and in c9orf72. There are already promising therapeutic approaches for the treatment of these diseases, but many questions, such as the exact course of the disease and its measurement or the best time to start treatment, still need to be answered.

Study Center

The DSGZ study center supports scientists in clinical research including design, biometrics (in close cooperation with the IBE), data management, regulatory compliance (in cooperation with the CSCLMU), insurance, training, funding. It offers infrastructure such as study assistance, quality management, electronic data capture (via eCRF), trial management system (TrackDB), contact to trial sites with experience in clinical vestibular research.

The DSGZ study center is also open to cooperation with institutions outside the DSGZ, for which, however, the CSCLMU should be the first point of contact within the KUM (Klinikum der Universität München).

Study Center

The DSGZ study center supports scientists in clinical research including design, biometrics (in close cooperation with the IBE), data management, regulatory compliance (in cooperation with the CSCLMU), insurance, training, funding. It offers infrastructure such as study assistance, quality management, electronic data capture (via eCRF), trial management system (TrackDB), contact to trial sites with experience in clinical vestibular research.

The DSGZ study center is also open to cooperation with institutions outside the DSGZ, for which, however, the CSCLMU should be the first point of contact within the KUM (Klinikum der Universität München).

Bruxism patients - teeth grinding

The aim of the study is to test biofeedback splint therapy. The therapeutic approach with this splint is to treat bruxism and eliminate the consequences in addition to the actual tooth protection.

With the splint to be tested, the patient should subconsciously learn to refrain from grinding during sleep through biofeedback. The body is shown the incorrect behavior through feedback. This splint consists of an elastic plastic dental splint, lies on the teeth in the upper jaw and also covers the palate area. Waterproof electronic components are encapsulated in the splint, which provide feedback (biofeedback) in the event of incorrect behavior (grinding/clenching). The duration of grinding and the time of grinding are recorded.

The recruitment phase has been completed. No further interested parties can be admitted to the study.